Soleno Therapeutics Files 8-K on Financials
Ticker: SLNO · Form: 8-K · Filed: 2024-05-10T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: SLNO
TL;DR
SOLENO THERAPEUTICS (SLNO) filed an 8-K on 5/9/24 detailing financials. Check it out.
AI Summary
On May 9, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Capnia, Inc., is incorporated in Delaware and headquartered in Redwood City, California. This filing provides updates on its financial condition and operational status.
Why It Matters
This 8-K filing provides investors with crucial, up-to-date information on Soleno Therapeutics' financial health and operational performance, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial and operational information, not indicating any immediate or significant new risks.
Key Players & Entities
- Soleno Therapeutics, Inc. (company) — Registrant
- Capnia, Inc. (company) — Former company name
- May 9, 2024 (date) — Date of earliest event reported
- Redwood City, CA (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for Soleno Therapeutics?
The primary purpose is to report on the company's results of operations and financial condition, as well as financial statements and exhibits, as of May 9, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on May 9, 2024.
What was Soleno Therapeutics' former company name?
Soleno Therapeutics, Inc.'s former company name was Capnia, Inc.
Where are Soleno Therapeutics' principal executive offices located?
Soleno Therapeutics' principal executive offices are located at 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065.
Under which section of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-09 19:36:05
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d767565d8k.htm (8-K) — 24KB
- d767565dex991.htm (EX-99.1) — 62KB
- g767565g81n21.jpg (GRAPHIC) — 5KB
- 0001193125-24-135478.txt ( ) — 221KB
- slno-20240509.xsd (EX-101.SCH) — 3KB
- slno-20240509_lab.xml (EX-101.LAB) — 18KB
- slno-20240509_pre.xml (EX-101.PRE) — 11KB
- d767565d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: May 10, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer